Respiratory Syncytial Virus Newsletter sign up now
-
Couple reluctantly seeks help after mold causes twins' potentially deadly illness
... Onyx Neidigh are fighting a potentially deadly respiratory virus that doctors say was contracted through exposure ... their babies are being treated for respiratory syncytial virus at Mary Bridge Children's Hospital and ...
-
UTSA, UT Health Science Center win $1.5M from S.A. Life Sciences Institute
... of National Mentoring Month activities Bio-pharmaceutical company ViroXis will be the first to move in ... and educational initiatives: Microencapsulated Delivery of Oncolytic Respiratory Syncytial Virus for Targeting Prostate Tumor In Vivo ...
-
The pediatrician's role in raising awareness of respiratory syncytial virus
...
-
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytom
... Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a ... immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead ...
-
Research and Markets: Antivirals: Novel Targets, Technologies, and Dealmaking
... new report " The hottest field in antivirals is hepatitis C virus (HCV) drug development; ... treatment, novel drug targets, development compounds, companies. Respiratory syncytial virus (RSV): virus and disease, current treatment, ...
- Don’t see the news you want? Customize your own newsletters. Sign up for a FREE TRIAL to the Inbox Robot Today. Click Here.
-
Biopharmaceutical Stock Alert for GenVec Inc. Issued by StockPreacher
... vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus and Herpes Simplex Virus Type 2 (HSV-2). "GNVC last week announced financial results ...
-
NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
... our trivalent seasonal VLP influenza vaccine and identified a viable vaccine candidate to prevent respiratory syncytial virus (RSV). We have now conducted five human clinical studies for our pandemic and ...
-
Novavax Posts Wider-Than-Expected Loss; Investors Flee (NVAX)
... our trivalent seasonal VLP influenza vaccine and identified a viable vaccine candidate to prevent respiratory syncytial virus (RSV). We have now conducted five human clinical studies for our pandemic and seasonal ...
-
GenVec Is Not Just a One Trick Pony
... is developing vaccines (using the same adenovector technology) for influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus [RSV], and HSV-2. The attention that GNVC has received (in the form of financial ...
-
GenVec Reports Fourth Quarter and 2009 Year-End Financial Results
... of HIV vaccine candidates with GenVec's alternate adenovirus serotype technology. -- We received a Phase ... diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers ...
- Don’t see the news you want? Customize your own newsletters. Sign up for a FREE TRIAL to the Inbox Robot Today. Click Here.
-
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update
... premature infants to adults, suffering from debilitating respiratory disorders. Our near term priorities are to ... serotype referred to as H1N1) or respiratory syncytial virus (RSV). Hospitalization following influenza or other viral ...
-
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
... Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a ... immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead ...
-
Medivation, Pfizer Disappointed Over Drug Failure - Biotech's Latest Mishaps
... and hepatitis C. It is also eliminating vaccine research other than for influenza and respiratory syncytial virus, AP reported. The company is closing research sites in the United Kingdom and Sweden. ...
-
GenVec to Present at the ROTH 22nd Annual Orange County Growth Stock Conference
... adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and ...
-
Alnylam to Webcast Presentation at the 22nd Annual ROTH OC Growth Stock Conference
... most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the treatment of ...
- Don’t see the news you want? Customize your own newsletters. Sign up for a FREE TRIAL to the Inbox Robot Today. Click Here.
Presswire
Press Release Distribution Service
- New CRM Kit Set To Launch March 23, 2010 Step To CRM Kit [17 Mar 2010]
News publications
- World News Report
- US Politics Today
- EU Politics Today
- Healthcare Industry Today
- Music Industry Today
- Agriculture Industry Today
- Energy Industry Today
- IT Industry Today
- Airline Industry Today
- Automotive Industry Today
- Finance Industry Today
© 2005-2010